NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

I don’t think that some really understand why I say that there will not be a need for separate regulatory approvals for the combination of DCVax-L + poly-ICLC.

When DCVax-L is approved by regulators in the US, Canada, UK, Germany and the rest of the EU, that means the combination of DCVax-L + poly-ICLC will also automatically be approved at the same time. The bottom line is DCVax-L + poly-ICLC is still DCVax-L.

NWBio has patented the processes for making DCVax-L.The processes involved for making DCVax-L include the following:

(1). Obtaining biological materials (tumor tissue, cells, blood, etc.) from each individual patient to make their own personalized vaccine.

(2). Separate out each patient’s dendritic cells.

(3) Add a maturation agent of NWBio’s choosing (on the DCVax-L patents there are several agents to choose from, including poly-ICLC).

(4) Add a activation agent of NWBio’s choosing (on the DCVax-L patents there are several agents to choose from, including poly-ICLC).

Take a look at what I asked ChatGPT, and the answers I got back: